Recreational and ergogenic substance use and substance use disorders in elite athletes: a narrative review.


Journal

British journal of sports medicine
ISSN: 1473-0480
Titre abrégé: Br J Sports Med
Pays: England
ID NLM: 0432520

Informations de publication

Date de publication:
Jun 2019
Historique:
accepted: 22 04 2019
pubmed: 18 5 2019
medline: 2 7 2019
entrez: 18 5 2019
Statut: ppublish

Résumé

Substances from various classes may be used for recreational purposes, self-treatment or to boost performance. When substance use shifts from occasional to regular, heavy or hazardous use, positive and negative effects can develop that vary by substance class and athlete. Regular use of recreational or performance enhancing substances can lead to misuse, sanctions or use disorders. To review the prevalence, patterns of use, risk factors, performance effects and types of intervention for all classes of recreational and performance enhancing substances in elite athletes by sport, ethnicity, country and gender. A comprehensive search was conducted to identify studies that compared the prevalence and patterns of substance use, misuse and use disorders in elite athletes with those of non-athletes and provided detailed demographic and sport variations in reasons for use, risk factors and performance effects for each main substance class. Alcohol, cannabis, tobacco (nicotine) and prescribed opioids and stimulants are the most commonly used substances in elite athletes, but generally used at lower rates than in non-athletes. In contrast, use/misuse rates for binge alcohol, oral tobacco, non-prescription opioids and anabolic-androgenic steroids are higher among athletes than non-athletes, especially in power and collision sports. Cannabis/cannabinoids seem to have replaced nicotine as the second most commonly used substance. Substance use in elite athletes varies by country, ethnicity, gender, sport and competitive level. There are no studies on substance use disorder prevalence in elite male and female athletes and few studies with direct comparison groups.

Sections du résumé

BACKGROUND BACKGROUND
Substances from various classes may be used for recreational purposes, self-treatment or to boost performance. When substance use shifts from occasional to regular, heavy or hazardous use, positive and negative effects can develop that vary by substance class and athlete. Regular use of recreational or performance enhancing substances can lead to misuse, sanctions or use disorders.
OBJECTIVE OBJECTIVE
To review the prevalence, patterns of use, risk factors, performance effects and types of intervention for all classes of recreational and performance enhancing substances in elite athletes by sport, ethnicity, country and gender.
METHODS METHODS
A comprehensive search was conducted to identify studies that compared the prevalence and patterns of substance use, misuse and use disorders in elite athletes with those of non-athletes and provided detailed demographic and sport variations in reasons for use, risk factors and performance effects for each main substance class.
RESULTS RESULTS
Alcohol, cannabis, tobacco (nicotine) and prescribed opioids and stimulants are the most commonly used substances in elite athletes, but generally used at lower rates than in non-athletes. In contrast, use/misuse rates for binge alcohol, oral tobacco, non-prescription opioids and anabolic-androgenic steroids are higher among athletes than non-athletes, especially in power and collision sports. Cannabis/cannabinoids seem to have replaced nicotine as the second most commonly used substance.
CONCLUSIONS CONCLUSIONS
Substance use in elite athletes varies by country, ethnicity, gender, sport and competitive level. There are no studies on substance use disorder prevalence in elite male and female athletes and few studies with direct comparison groups.

Identifiants

pubmed: 31097457
pii: bjsports-2019-100669
doi: 10.1136/bjsports-2019-100669
doi:

Substances chimiques

Performance-Enhancing Substances 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

754-760

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

David McDuff (D)

Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA dmcduff52@gmail.com.
MD Sports Performance, Ellicott, Maryland, USA.

Todd Stull (T)

Athletics, University of Nebraska-Lincoln University Health Center, Lincoln, Nebraska, USA.

João Mauricio Castaldelli-Maia (JM)

Department of Psychiatry, Medical School, University of São Paulo, São Paulo, Brazil.
Department of Neuroscience, Medical School, Fundação do ABC, Santo André, Brazil.

Mary E Hitchcock (ME)

Ebling Library for the Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Brian Hainline (B)

National Collegiate Athletic Association (NCAA), Indianapolis, Indiana, USA.

Claudia L Reardon (CL)

Department of Psychiatry, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH